These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33687063)

  • 21. Surgeon training and use of radioactive iodine in stage I thyroid cancer patients.
    Schuessler KM; Banerjee M; Yang D; Stewart AK; Doherty GM; Haymart MR
    Ann Surg Oncol; 2013 Mar; 20(3):733-8. PubMed ID: 23224826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practice patterns among thyroid cancer surgeons: implications of performing a prophylactic central neck dissection.
    Deutschmann MW; Chin-Lenn L; Nakoneshny SC; Dort JC; Pasieka JL; Chandarana SP
    J Otolaryngol Head Neck Surg; 2016 Oct; 45(1):55. PubMed ID: 27793192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in Population-Level and Institutional-Level Prescribing Habits of Radioiodine Therapy for Papillary Thyroid Cancer.
    Jacobs D; Breen CT; Pucar D; Holt EH; Judson BL; Mehra S
    Thyroid; 2021 Feb; 31(2):272-279. PubMed ID: 32811347
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of radioactive iodine for thyroid cancer.
    Haymart MR; Banerjee M; Stewart AK; Koenig RJ; Birkmeyer JD; Griggs JJ
    JAMA; 2011 Aug; 306(7):721-8. PubMed ID: 21846853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Energy level and fatigue after surgery for thyroid cancer: A population-based study of patient-reported outcomes.
    Hughes DT; Reyes-Gastelum D; Kovatch KJ; Hamilton AS; Ward KC; Haymart MR
    Surgery; 2020 Jan; 167(1):102-109. PubMed ID: 31582311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
    Zevallos JP; Xu L; Yiu Y
    Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective use of radioactive iodine (RAI) in thyroid cancer: No longer "one size fits all".
    Marti JL; Morris LGT; Ho AS
    Eur J Surg Oncol; 2018 Mar; 44(3):348-356. PubMed ID: 28545679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between extent of thyroid cancer surgery and use of radioactive iodine.
    Haymart MR; Banerjee M; Yang D; Stewart AK; Doherty GM; Koenig RJ; Griggs JJ
    Ann Surg; 2013 Aug; 258(2):354-8. PubMed ID: 23567930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.
    Mei X; Yao X; Feng F; Cheng W; Wang H
    BMC Cancer; 2021 May; 21(1):543. PubMed ID: 33980182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer.
    Haymart MR; Banerjee M; Yang D; Stewart AK; Koenig RJ; Griggs JJ
    Cancer; 2013 Jan; 119(2):259-65. PubMed ID: 22744940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. INITIAL ADOPTION OF RECOMBINANT HUMAN THYROID-STIMULATING HORMONE FOLLOWING THYROIDECTOMY IN THE MEDICARE THYROID CANCER PATIENT POPULATION.
    Dinan MA; Li Y; Reed SD; Sosa JA
    Endocr Pract; 2019 Jan; 25(1):31-42. PubMed ID: 30383499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with physicians' recommendations for managing low-risk papillary thyroid cancer.
    McDow AD; Roman BR; Saucke MC; Jensen CB; Zaborek N; Jennings JL; Davies L; Brito JP; Pitt SC
    Am J Surg; 2021 Jul; 222(1):111-118. PubMed ID: 33248684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
    Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
    Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
    Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
    World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
    van Velsen EFS; Visser WE; van den Berg SAA; Kam BLR; van Ginhoven TM; Massolt ET; Peeters RP
    Thyroid; 2020 Apr; 30(4):580-587. PubMed ID: 31928168
    [No Abstract]   [Full Text] [Related]  

  • 37. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    Pasqual E; Schonfeld S; Morton LM; Villoing D; Lee C; Berrington de Gonzalez A; Kitahara CM
    J Clin Oncol; 2022 May; 40(13):1439-1449. PubMed ID: 35044839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
    Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
    Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anxiety and depression status prior to radioactive iodine therapy among differentiated thyroid cancer patients during the COVID‑19 pandemic.
    Qiao T; Gao D; Tong J; Shen Y; Ma J; Lv Z; Li D
    Support Care Cancer; 2022 Dec; 30(12):10169-10177. PubMed ID: 36326909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation for radioactive iodine therapy is not a risk factor for the development of hyponatremia in thyroid cancer patients.
    Kim J; Cho SG; Kang SR; Kwon SY; Cho DH; Cho JS; Song HC
    Medicine (Baltimore); 2017 Feb; 96(5):e6004. PubMed ID: 28151897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.